The Zhitong Finance App learned that CICC released a research report saying that considering the R&D expenses brought about by the company speeding up core global clinical enrollment, the target price is HK$45, which is 35.2% upward compared to the current stock price. Considering the company's long-term value in advancing global R&D, the bank maintained its outperforming industry rating.

The Zhitong Finance App learned that CICC released a research report saying that considering the R&D expenses brought about by the company speeding up core global clinical enrollment, the target price is HK$45, which is 35.2% upward compared to the current stock price. Considering the company's long-term value in advancing global R&D, the bank maintained its outperforming industry rating.